|
Neoadjuvant cisplatin-based chemotherapy in patients with ureteral obstruction secondary to muscle invasive bladder cancer. |
|
|
No Relationships to Disclose |
|
|
Leadership - Visible Health |
Stock and Other Ownership Interests - Visible Health |
Consulting or Advisory Role - Pfizer; UroToday |
Travel, Accommodations, Expenses - Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Pfizer (Inst); Pfizer (Inst); Pfizer (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - EMD Serono; Horizon Pharma; Janssen; Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); Horizon Pharma (Inst); Pfizer (Inst) |
Other Relationship - Association of Community Cancer Centers (ACCC) |
|
|
Consulting or Advisory Role - Genentech/Roche; Pfizer; Urogen pharma |
Speakers' Bureau - Janssen Oncology |
Research Funding - Novartis |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Flatiron Health; Genentech/Roche; Incyte; Janssen; Merck; Pfizer; Seagen |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); Peloton Therapeutics (Inst); Pfizer (Inst) |
Patents, Royalties, Other Intellectual Property - U.S. Patent No.: 14/588,503, Filed 1/2/2015. (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca; Eisai; Exelixis; Pfizer; Seattle Genetics/Astellas |
Research Funding - Astellas Pharma (Inst); Calithera Biosciences (Inst); Genentech (Inst); Merck (Inst) |